Mode
Text Size
Log in / Sign up
N/A N=385 Randomized Single-blind Prevention

Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix

Preterm Birth

Enrolled (actual)
385
Serious AEs
0.0%
Results posted
Mar 2021
Primary outcome: Primary: Spontaneous Delivery Before 34 Completed Weeks — 51; 12 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Silicon ring (Arabin Pessary) (Device)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Maternal-Infantil Vall d´Hebron Hospital
Primary completion
Jul 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Spontaneous Delivery Before 34 Completed Weeks
51; 12
SECONDARY
Birthweight Less Than 1500 g
26; 9
SECONDARY
Birthweight Less Than 2500 g
56; 17
SECONDARY
Intrauterine Fetal Demise
0; 0
SECONDARY
Neonatal Death
1; 0
SECONDARY
Intraventricular Haemorrhage
2; 0
SECONDARY
Respiratory Distress Syndrome
23; 5
SECONDARY
Retinopathy of Prematurity
2; 0
SECONDARY
Necrotising Enterocolitis
2; 0
SECONDARY
Treatment for Sepsis
12; 3
SECONDARY
Composite Adverse Outcomes
30; 5
SECONDARY
Spontaneous Delivery Before 28 Completed Weeks
16; 4
SECONDARY
Any Delivery Before 34 Completed Weeks
53; 14
SECONDARY
Spontaneous Delivery Before 37 Completed Weeks
113; 41
SECONDARY
Gestational Age at Delivery
34.9; 37.7
SECONDARY
Use of Tocolysis
101; 64
SECONDARY
Use of Antenatal Steroids
121; 80
SECONDARY
Chorioamnionitis
6; 5
SECONDARY
Vaginal Bleeding
9; 7
SECONDARY
Preterm Premature Rupture of Membranes
17; 3
SECONDARY
Cesarean Delivery
40; 41
SECONDARY
Vaginal Discharge
87; 190
SECONDARY
Pessary Repositioning Without Removal
0; 27
SECONDARY
Pessary Withdrawal
0; 1

Summary

Placement of a vaginal pessary reduces significantly the rate of spontaneous preterm birth in pregnant women with short cervical length at 18-22 weeks scan.

Eligibility Criteria

Inclusion Criteria

  • Singleton pregnancy
  • Minimal age of 18 years

Exclusion Criteria

  • Major fetal abnormalities (requiring surgery or leading to infant death or severe handicap)
  • SROM at the time of randomization
  • Cervical cerclage in situ
  • Active vaginal bleeding
  • Previous cone biopsy or cerclage
  • Major uterine structural anomalies
  • Placenta previa
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00706264). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search